Beyond Biotech podcast 63 – Fighting cancer with STRIs

cancer tumor

This week’s podcast is sponsored by Vetter.

On this week’s episode, we have a conversation with Steve Worland, CEO of eFFECTOR Therapeutics. eFFECTOR is a clinical-stage biopharmaceutical company pioneering the development of a new class of cancer drugs referred to as STRIs (selective translation regulation inhibitors). 

eFFECTOR’s STRI product candidates target the eIF4F complex and its activating kinase, mitogen-activated protein kinase interacting kinase (MNK). The eIF4F complex is a central node where two of the most frequently mutated signaling pathways in cancer, the PI3K-AKT and RAS-MEK pathways, converge to activate the translation of select mRNA into proteins that are frequent culprits in key disease-driving processes. 

The company’s product candidates are designed to act on a single protein that drives the expression of a network of functionally related proteins, including oncoproteins and immunosuppressive proteins in T cells, that together control tumor growth, survival and immune evasion. 

The lead product candidate, tomivosertib, is an MNK inhibitor currently being evaluated in KICKSTART, a randomized, double-blind, placebo-controlled phase 2b trial of tomivosertib in combination with pembrolizumab in patients with metastatic non-small cell lung cancer (NSCLC). 

Zotatifin, eFFECTOR’s inhibitor of eIF4A, is currently being evaluated in phase 2a expansion cohorts in certain biomarker-positive solid tumors, including ER+ breast cancer and KRAS-mutant NSCLC.

eFFECTOR has a global collaboration with Pfizer to develop inhibitors of a third target, eIF4E.

Over 2,000 biopharma companies including 90% of the Top 50 pharma companies use Connect for Biotech for year-round partnering.

Join us on 19 September 4pm CET | 10am EDT with Rajika Perera, Co-Founder & CEO at Poseidon LLC, and Robin Knight, Global Chief Product Officer at Inova, as they explore how to leverage Connect for Biotech to showcase assets, engage in conversations with potential partners, and receive valuable feedback from in-licensors.

Newsletter Signup - Under Article

"*" indicates required fields

Subscribe to our newsletter to get the latest biotech news!

This field is for validation purposes and should be left unchanged.

Suggested Articles

Show More